Halozyme Therapeutics, Inc. (HALO) Tops Q3 EPS by 9c, Sales Beat Expectations
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $103.00 +4.40%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q3 EPS of $0.05, $0.09 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $22.9 million versus the consensus estimate of $19.25 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
- Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
